Silence Therapeutics reports Q2 2026 results and divesiran trial progress
The company finished dosing all patients in the Phase 2 SANRECO trial for divesiran and reported $72.1 million in cash as of June 30, 2026.
Silence Therapeutics plc reported financial and business results for the quarter ended June 30, 2026 on August 10, 2026.
For divesiran, the company's siRNA candidate targeting TMPRSS6 for polycythemia vera and other blood disorders, Silence presented follow-up data from the Phase 1 SANRECO trial at the European Hematology Association 2026 Annual Congress in June 2026, showing durable efficacy results and what the company described as a potential best-in-class profile in PV.1
In the same month, the company finished dosing all patients in the Phase 2 SANRECO trial, a double-blind, placebo-controlled study testing divesiran at 6 mg/kg on two dosing schedules, every six weeks and every twelve weeks, in 48 patients with phlebotomy-dependent polycythemia vera.1
Separately, the American Journal of Hematology published a preclinical study by Silence scientists in June 2026 examining TMPRSS6 silencing as a possible treatment approach for myelodysplastic syndrome.1
On the AstraZeneca-partnered program, Phase 1 results for SLN312 (AZD1705), an ANGPTL3-targeting siRNA for dyslipidemia, were presented by AstraZeneca at the European Atherosclerosis Society Congress in May, showing a favorable safety profile along with dose-dependent, durable reductions in ANGPTL3 protein and in atherogenic lipoproteins including LDL-C, Apo-B and non-HDL-C.1
On the preclinical side, Silence said additional data showed the lipid-lowering effect of SLN365 (GPR146) was not altered by co-treatment with a statin or with ezetimibe, and the company said the program is positioned for a possible IND filing in 2027.1 For SLN098 (INHBE), new data in a diet-induced obesity mouse model showed reduced visceral fat and preserved lean body mass, and the company likewise said this program could support an IND filing in 2027.1
On finances, cash and cash equivalents stood at $72.1 million as of June 30, 2026.1 Research and development expenses fell to $9.1 million for the quarter, down from $17.6 million a year earlier, which the company attributed mainly to completion of Phase 3 readiness work for zerlasiran in 2025 and lower personnel costs.1 Net loss for the quarter was $12.3 million, or $0.09 per share, compared with a $27.4 million loss, or $0.19 per share, in the prior-year period.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.